Breaking News

Mayne Pharma Appoints Blake Cullen VP of Business Development for US Generics

June 16, 2014

Mayne Pharma has apointed Blake Cullen VP of Business Development for its U.S. generic products division.  Mr. Cullen brings over 15 years of industry experience to the position, in the areas of strategic planning, mergers and acquisitions, product in-licensing and out-licensing for companies such as Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco labs.  With a J.D. degree and an MBA from the University of Cincinnati and a B.S. from Seton Hall, Mr. Cullen has also served as general counsel at Qualitest Pharmaceuticals.  Mayne's generics business, established less than 10 years ago, currently markets more than 20 products and is developing 25 new products, with 13 ANDAs filed with FDA.  Expanding this portfolio will come through both organic development and bolt on acquisitions, said Stefan Cross, Mayne Pharma's president. "Blake brings a strong track record of building pharmaceutical product lines and corporate value," Cross said. 

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks